BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kalathil SG, Hutson A, Barbi J, Iyer R, Thanavala Y. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight 2019;4:130116. [PMID: 31391334 DOI: 10.1172/jci.insight.130116] [Cited by in Crossref: 24] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Xiong DD, Li JD, He RQ, Li MX, Pan YQ, He XL, Dang YW, Chen G. Highly expressed carbohydrate sulfotransferase 11 correlates with unfavorable prognosis and immune evasion of hepatocellular carcinoma. Cancer Med 2022. [PMID: 36062845 DOI: 10.1002/cam4.5186] [Reference Citation Analysis]
2 Xu X, Fan Z, Wang Y, Huang F, Xu Y, Sun J, Xu N, Deng L, Li X, Liang X, Luo X, Shi P, Liu H, Chen Y, Tu S, Huang X, Liu Q, Xuan L. Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial. BMC Med 2022;20:282. [PMID: 36050712 DOI: 10.1186/s12916-022-02479-x] [Reference Citation Analysis]
3 Cheng CC, Ho AS, Peng CL, Chang J, Sie ZL, Wang CL, Chen YL, Chen CY. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8+ T cell activation to eradicate hepatocellular carcinoma. Int Immunopharmacol 2022;112:109110. [PMID: 36037651 DOI: 10.1016/j.intimp.2022.109110] [Reference Citation Analysis]
4 Zhang T, Zhang C, Fu Z, Gao Q. Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy. Pharmaceutics 2022;14:1768. [DOI: 10.3390/pharmaceutics14091768] [Reference Citation Analysis]
5 Shi Y, Shang J, Li Y, Zhong D, Zhang Z, Yang Q, Lai C, Feng T, Yao Y, Huang X. ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma. Cancer Med 2022. [PMID: 35946175 DOI: 10.1002/cam4.5110] [Reference Citation Analysis]
6 Zhang CY, Liu S, Yang M. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World J Gastroenterol 2022; 28(27): 3346-3358 [DOI: 10.3748/wjg.v28.i27.3346] [Reference Citation Analysis]
7 Riaz F, Wei P, Pan F. Fine-tuning of regulatory T cells is indispensable for the metabolic steatosis-related hepatocellular carcinoma: A review. Front Cell Dev Biol 2022;10:949603. [DOI: 10.3389/fcell.2022.949603] [Reference Citation Analysis]
8 Li B, Zhang X, Wu Z, Chu T, Yang Z, Xu S, Wu S, Qie Y, Lu Z, Qi F, Hu M, Zhao G, Wei J, Zhao Y, Nie G, Meng H, Liu R, Li S. Reducing Postoperative Recurrence of Early-Stage Hepatocellular Carcinoma by a Wound-Targeted Nanodrug. Adv Sci (Weinh) 2022;:e2200477. [PMID: 35524631 DOI: 10.1002/advs.202200477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun 2022. [PMID: 35481940 DOI: 10.1002/hep4.1927] [Reference Citation Analysis]
10 Jiguet-Jiglaire C, Boissonneau S, Denicolai E, Hein V, Lasseur R, Garcia J, Romain S, Appay R, Graillon T, Mason W, Carpentier AF, Brandes AA, Ouafik L', Wick W, Baaziz A, Gigan JP, Argüello RJ, Figarella-Branger D, Chinot O, Tabouret E. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta Neuropathol Commun 2022;10:1. [PMID: 34980260 DOI: 10.1186/s40478-021-01305-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zhang C, Yang M. Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion. Front Med (Lausanne) 2021;8:789859. [PMID: 34869507 DOI: 10.3389/fmed.2021.789859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hao X, Sun G, Zhang Y, Kong X, Rong D, Song J, Tang W, Wang X. Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges. Front Cell Dev Biol 2021;9:775462. [PMID: 34869376 DOI: 10.3389/fcell.2021.775462] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
13 Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. World J Gastrointest Oncol 2021; 13(11): 1616-1631 [PMID: 34853639 DOI: 10.4251/wjgo.v13.i11.1616] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Paillet J, Plantureux C, Lévesque S, Le Naour J, Stoll G, Sauvat A, Caudana P, Tosello Boari J, Bloy N, Lachkar S, Martins I, Opolon P, Checcoli A, Delaune A, Robil N, de la Grange P, Hamroune J, Letourneur F, Autret G, Leung PSC, Gershwin ME, Zhu JS, Kurth MJ, Lekbaby B, Augustin J, Kim Y, Gujar S, Coulouarn C, Fouassier L, Zitvogel L, Piaggio E, Housset C, Soussan P, Maiuri MC, Kroemer G, Pol JG. Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. J Exp Med 2021;218:e20200853. [PMID: 34495298 DOI: 10.1084/jem.20200853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Duan X, Cai Y, He T, Shi X, Zhao J, Zhang H, Shen Y, Zhang H, Zhang H, Duan W, Jiang B, Mao X. The effect of the TP53 and RB1 mutations on the survival of hepatocellular carcinoma patients with different racial backgrounds. J Gastrointest Oncol 2021;12:1786-96. [PMID: 34532128 DOI: 10.21037/jgo-21-312] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Hutson AD. An Accelerated Life Model Analog for Discrete Survival and Count Data. Comput Methods Programs Biomed 2021;210:106337. [PMID: 34469807 DOI: 10.1016/j.cmpb.2021.106337] [Reference Citation Analysis]
17 Aghabi YO, Yasin A, Kennedy JI, Davies SP, Butler AE, Stamataki Z. Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer. Front Immunol 2021;12:662134. [PMID: 33953725 DOI: 10.3389/fimmu.2021.662134] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
18 Bourhis M, Palle J, Galy-Fauroux I, Terme M. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. Front Immunol 2021;12:616837. [PMID: 33854498 DOI: 10.3389/fimmu.2021.616837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ding H, Hu H, Tian F, Liang H. A dual immune signature of CD8+ T cells and MMP9 improves the survival of patients with hepatocellular carcinoma. Biosci Rep 2021;41:BSR20204219. [PMID: 33656546 DOI: 10.1042/BSR20204219] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Zhao L, Fu X, Han X, Yu Y, Ye Y, Gao J. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma. Cancer Cell Int 2021;21:80. [PMID: 33509222 DOI: 10.1186/s12935-021-01774-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chen M, Brackett CM, Burdelya LG, Punnanitinont A, Patnaik SK, Matsuzaki J, Odunsi AO, Gudkov AV, Singh AK, Repasky EA, Gurova KV. Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy. Cancer Immunol Immunother 2021;70:2073-86. [PMID: 33439292 DOI: 10.1007/s00262-020-02846-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H, Fragomeli V, Koay YC, Jackson M, O'Sullivan J, Weltman M, McCaughan G, El-Omar E, Zekry A. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 2021;12:187. [PMID: 33420074 DOI: 10.1038/s41467-020-20422-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 62] [Article Influence: 13.0] [Reference Citation Analysis]
23 Kalathil SG, Thanavala Y. Importance of myeloid derived suppressor cells in cancer from a biomarker perspective. Cell Immunol 2021;361:104280. [PMID: 33445053 DOI: 10.1016/j.cellimm.2020.104280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
24 Li Y, Xie J, Um W, You DG, Kwon S, Zhang L, Zhu J, Park JH. Sono/Photodynamic Nanomedicine‐Elicited Cancer Immunotherapy. Adv Funct Mater 2021;31:2008061. [DOI: 10.1002/adfm.202008061] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
25 Hirose S, Ishige K, Yamaura M, Mizui T, Komatsu Y, Nagase M, Sato M, Hattori J, Endo M, Hasegawa N, Fukuda K, Hyodo I. A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy. Clin J Gastroenterol 2020;13:902-6. [PMID: 32557088 DOI: 10.1007/s12328-020-01154-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kalathil SG, Wang K, Hutson A, Iyer R, Thanavala Y. Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients. Oncoimmunology 2020;9:1824863. [PMID: 33101775 DOI: 10.1080/2162402X.2020.1824863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
27 Chen W, Bi K, Zhang X, Jiang J, Diao H. In-depth characterization of the biomarkers based on tumor-infiltrated immune cells reveals implications for diagnosis and prognosis in hepatocellular carcinoma. J Transl Autoimmun 2020;3:100067. [PMID: 33073226 DOI: 10.1016/j.jtauto.2020.100067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188382. [PMID: 32522600 DOI: 10.1016/j.bbcan.2020.188382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
29 Jayant K, Habib N, Huang KW, Warwick J, Arasaradnam R. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics (Basel). 2020;10. [PMID: 32466214 DOI: 10.3390/diagnostics10050338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
30 Sun X, Cao Z, Mao K, Wu C, Chen H, Wang J, Wang X, Cong X, Li Y, Meng X, Yang X, Yang Y, Sun T. Photodynamic therapy produces enhanced efficacy of antitumor immunotherapy by simultaneously inducing intratumoral release of sorafenib. Biomaterials 2020;240:119845. [DOI: 10.1016/j.biomaterials.2020.119845] [Cited by in Crossref: 22] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
31 Bresnahan E, Lindblad KE, Ruiz de Galarreta M, Lujambio A. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. Clin Cancer Res 2020;26:5276-86. [PMID: 32327473 DOI: 10.1158/1078-0432.CCR-19-2923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
32 Wo YJ, Gan ASP, Lim X, Tay ISY, Lim S, Lim JCT, Yeong JPS. The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy. Cells 2019;9:E26. [PMID: 31861847 DOI: 10.3390/cells9010026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
33 Prado MCM, Macedo SAL, Guiraldelli GG, de Faria Lainetti P, Leis-Filho AF, Kobayashi PE, Laufer-Amorim R, Fonseca-Alves CE. Investigation of the Prognostic Significance of Vasculogenic Mimicry and Its Inhibition by Sorafenib in Canine Mammary Gland Tumors. Front Oncol 2019;9:1445. [PMID: 31921690 DOI: 10.3389/fonc.2019.01445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]